These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 16715299)

  • 1. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
    Wei J; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
    Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
    Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
    Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
    Cermák J; Vítek A; Michalová K
    Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification].
    Yu MH; Liu SH; Shao YQ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):482-5. PubMed ID: 15555265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome.
    Lee JH; Lee JH; Shin YR; Lee JS; Kim WK; Chi HS; Park CJ; Seo EJ; Lee KH
    Leukemia; 2003 Feb; 17(2):305-13. PubMed ID: 12592327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
    Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
    J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
    Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
    Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes.
    Breccia M; Carmosino I; Biondo F; Mancini M; Russo E; Latagliata R; Alimena G
    Leuk Res; 2006 Feb; 30(2):178-82. PubMed ID: 16102825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
    Wang H; Wang XQ; Xu XP; Lin GW
    Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.